VAT N° 01537970525
News and Publications
Scrivi un titolo accattivante.
Utilizza questo spazio per scrivere i testi del tuo sito web. Ricordati di eliminare tutto ciò che è superfluo e tutto quello che non aggiunge nulla di nuovo ai tuoi testi. In questo modo riuscirai a catturare l’attenzione dei visitatori sui contenuti del tuo sito web.
October 2023
We are pleased to announce the approval of the Italian Patent Application (N. 102021000021764) for our anti-CD93 antibody.
September 2022
UCme BioScience was selected by G-Factor, the Golinelli Foundation's accelerator incubator, through the "I-Tech Innovation Program" call for proposals issued by Fondazione Golinelli and CRIF. The 2022 call received 247 applications in five areas: Life Sciences/Digital Health (3 selected startups), Fintech/Insurtech (2 selected startups), FoodTech/Agritech (1 selected startup), Industry 4.0 (2 selected startups) and Social Impact (2 selected startups). 1.5 million euros were invested for the startups.
Publications
THE CHARACTERIZATION OF A NOVEL MONOCLONAL ANTIBODY AGAINST CD93 UNVEILS A NEW ANTIANGIOGENIC TARGET
Oncotarget. 2014 May 15;5(9):2750-60. doi: 10.18632/oncotarget.1887.
The novel monoclonal antibody anti-CD93 is able to neutralize new vessel formation both in vitro and in vivo without affecting endothelial cell survival. For the first time, CD93 has been identified as a novel target for anti-angiogenic therapy.
J Cell Physial. 2017 Jul;232(7):1767-1773. doi:10.1002/jcp.25689
Transmembrane and soluble CD93 are overexpressed in patients with neovascular AMD, indicating that CD93 may represent a potential new antiangiogenic target in the treatement of choroidal neovascularization.
Invest Ophthalmal Vis Sci. 2020 Jul 1;61(8):30. doi: 10.1167/iovs.61.8.30
CD93 and its interatcion with Multimerin-2 play an important role in pathological vascularization of the choroid, disclosing new possibilities for theraupetic intervention to neovascular AMD.
Matrix Biol. 2017 Dec;64:112-127. doi: 10.1016/j.matbio.2017.08.003. Epub 2017 Sep 11.
Identification of Multimerin 2 (MMRN2), a pan-endothelial extracellular matrix protein, as a specific ligand for CD93.
Oncotarget. 2016 Mar 1;7(9):10090-103. doi: 10.18632/oncotarget.7136.
CD93 and dystroglycan cooperate in promoting endothelial cell adhesion and migration during angiogenesis involving c-Src.